VCYT Logo

Veracyte, Inc. (VCYT) 

NASDAQ
Market Cap
$3.19B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
932 of 958
Rank in Industry
531 of 549

Largest Insider Buys in Sector

VCYT Stock Price History Chart

VCYT Stock Performance

About Veracyte, Inc.

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, …

Insider Activity of Veracyte, Inc.

Over the last 12 months, insiders at Veracyte, Inc. have bought $0 and sold $7.63M worth of Veracyte, Inc. stock.

On average, over the past 5 years, insiders at Veracyte, Inc. have bought $525,242 and sold $42.27M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 60,000 shares for transaction amount of $980,094 was made by Stapley Marc (Chief Executive Officer) on 2022‑06‑10.

List of Insider Buy and Sell Transactions, Veracyte, Inc.

2024-12-13SaleChief Executive Officer
5,590
0.0072%
$43.42$242,737-3.71%
2024-12-04SaleChief Scientific & Med Officer
3,934
0.0051%
$44.09$173,447-2.52%
2024-12-04SaleSVP, General Counsel
18,699
0.024%
$44.02$823,179-2.52%
2024-12-03SaleChief Financial Officer
7,000
0.009%
$43.23$302,622-1.28%
2024-12-03SaleChief Commercial Officer-CLIA
1,050
0.0014%
$43.25$45,408-1.28%
2024-12-03SaleVP, Chief Accounting Officer
956
0.0012%
$43.36$41,452-1.28%
2024-11-27SaleVP, Chief Accounting Officer
5,032
0.0065%
$42.89$215,834+0.77%
2024-11-19Saledirector
14,731
0.0188%
$38.34$564,768-0.33%
2024-11-12SaleChief Financial Officer
15,275
0.0198%
$38.34$585,663+12.03%
2024-11-12Saledirector
15,000
0.0195%
$38.32$574,830+12.03%
2024-09-19Saledirector
5,173
0.0067%
$35.23$182,263+3.65%
2024-09-04SaleChief Commercial Officer-CLIA
5,479
0.0072%
$29.78$163,159+18.12%
2024-08-13Saledirector
24,326
0.0341%
$32.04$779,456+6.20%
2024-08-13Saledirector
47,645
0.0671%
$32.20$1.53M0.00%
2024-08-12Saledirector
200
0.0003%
$30.00$6,001+14.67%
2024-08-09Saledirector
1,778
0.0024%
$30.03$53,391+17.22%
2024-08-07Saledirector
5,108
0.0075%
$30.32$154,883+26.65%
2024-08-07Saledirector
5,000
0.007%
$29.00$145,000+26.65%
2024-07-16SaleChief Commercial Officer-CLIA
1,277
0.0019%
$25.00$31,925+32.24%
2024-07-16Saledirector
7,500
0.0109%
$25.00$187,500+32.24%

Insider Historical Profitability

5.66%
Stapley MarcChief Executive Officer
307345
0.3966%
$41.1811+45.22%
Holstein Jensdirector
27878
0.036%
$41.1813+12.01%
Anderson Bonnie Hdirector
42681
0.0551%
$41.18451+38.63%
Brooks JulieEVP,General Counsel, Secretary
3122
0.004%
$41.1840<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$163.65M9.667.38M+3.75%+$5.91M<0.01
Wellington Management Company$163.26M9.647.37M+4.23%+$6.63M0.03
BlackRock$159.8M9.437.21M+0.69%+$1.1M<0.01
ARK Investment Management LLC$156.07M9.217.04M-8.01%-$13.58M0.54
State Street$95.89M5.664.33M+39.19%+$27M<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.